|
KMID : 1011720210140020135
|
|
International Journal of Thyroidology
2021 Volume.14 No. 2 p.135 ~ p.142
|
|
|
Null Association between BRAF V600E Mutation and Tumor Recurrence in Patients with Papillary Thyroid Microcarcinoma in South Korea
|
|
Kim Ji-Yoon
Kim Kyoung-Jin
Bae Jae-Hyun
Kim Joo-Hyung
Kim Nam-Hoon
Kim Hee-Young
Kim Hoon-Yub
Baek Seung-Kuk
Kim Sin-Gon
Jung Kwang-Yoon
Kim Kyeong-Jin
|
|
|
Abstract
|
|
|
Background and Objectives: The clinical implications of the BRAF V600E mutation in papillary thyroid microcarcinoma (PTMC), defined as ≤1.0 cm of tumor size, remain controversial. We investigated the association between the BRAF V600E mutation and PTMC recurrence in a retrospective cohort of patients with thyroid cancer.
Materials and Methods: This study included 2319 patients with PTMC (median age, 50 years [interquartile range (IQR), 41-57 years]) who underwent thyroid surgery from 2010 to 2019 at a single tertiary medical center. The median follow-up time was 75 months (IQR, 30-98 months). Tumor recurrence was confirmed by histological, cytological, radiographic, and biochemical criteria, combined with persistent and recurrent disease.
Results: A total of 60.2% (1395/2319) patients with PTMC had the BRAF V600E mutation. The tumor recurrence rate was 2.1% (19/924) in BRAF mutation-negative patients and 2.9% (41/1395) in BRAF mutation-positive patients, with a hazard ratio (HR) of 1.05 (95% confidence interval [CI], 0.61-1.84) after adjusting for clinicopathological risk factors. Similar results were found in patients with high-risk PTMC (adjusted HR, 1.09; 95% CI, 0.56-2.11) who had lymph node metastasis (LNM), extrathyroidal extension (ETE), or distant metastasis (DM) at diagnosis and in patients with low-risk PTMC (adjusted HR, 1.00; 95% CI, 0.35-2.83) who had no LNM, ETE, or DM.
Conclusion: The finding that the BRAF V600E mutation was not associated with tumor recurrence in our cohort of Korean patients with PTMC, especially in patients with low-risk PTMC, suggests that its value in the prediction of disease progression is limited.
|
|
|
KEYWORD
|
|
|
Papillary thyroid microcarcinoma, BRAF V600E mutation, Active surveillance, Tumor recurrence
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|